138 related articles for article (PubMed ID: 24524665)
1. Improvements in algorithms for phenotype inference: the NAT2 example.
Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
Curr Drug Metab; 2014 Feb; 15(2):233-49. PubMed ID: 24524665
[TBL] [Abstract][Full Text] [Related]
2. Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype.
Selinski S; Blaszkewicz M; Lehmann ML; Ovsiannikov D; Moormann O; Guballa C; Kress A; Truss MC; Gerullis H; Otto T; Barski D; Niegisch G; Albers P; Frees S; Brenner W; Thüroff JW; Angeli-Greaves M; Seidel T; Roth G; Dietrich H; Ebbinghaus R; Prager HM; Bolt HM; Falkenstein M; Zimmermann A; Klein T; Reckwitz T; Roemer HC; Löhlein D; Weistenhöfer W; Schöps W; Hassan Rizvi SA; Aslam M; Bánfi G; Romics I; Steffens M; Ekici AB; Winterpacht A; Ickstadt K; Schwender H; Hengstler JG; Golka K
Pharmacogenet Genomics; 2011 Oct; 21(10):673-8. PubMed ID: 21750470
[TBL] [Abstract][Full Text] [Related]
3. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Selinski S; Blaszkewicz M; Ickstadt K; Hengstler JG; Golka K
Arch Toxicol; 2013 Dec; 87(12):2129-39. PubMed ID: 24221535
[TBL] [Abstract][Full Text] [Related]
4. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2.
Zang Y; Doll MA; Zhao S; States JC; Hein DW
Carcinogenesis; 2007 Aug; 28(8):1665-71. PubMed ID: 17434923
[TBL] [Abstract][Full Text] [Related]
5. A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background.
García-Closas M; Hein DW; Silverman D; Malats N; Yeager M; Jacobs K; Doll MA; Figueroa JD; Baris D; Schwenn M; Kogevinas M; Johnson A; Chatterjee N; Moore LE; Moeller T; Real FX; Chanock S; Rothman N
Pharmacogenet Genomics; 2011 Apr; 21(4):231-6. PubMed ID: 20739907
[TBL] [Abstract][Full Text] [Related]
6. tagSNP rs1495741 as a useful molecular marker to predict antituberculosis drug-induced hepatotoxicity.
Chamorro JG; Castagnino JP; Musella RM; Nogueras M; Frías A; Visca M; Aidar O; Costa L; de Larrañaga GF
Pharmacogenet Genomics; 2016 Jul; 26(7):357-61. PubMed ID: 27104815
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of N-acetyltransferase 2 (NAT2) gene polymorphism in shanghai population: occupational and non-occupational bladder cancer patient groups.
Ma QW; Lin GF; Chen JG; Xiang CQ; Guo WC; Golka K; Shen JH
Biomed Environ Sci; 2004 Sep; 17(3):291-8. PubMed ID: 15602826
[TBL] [Abstract][Full Text] [Related]
8. Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay.
Rihs HP; John A; Scherenberg M; Seidel A; Brüning T
Clin Chim Acta; 2007 Feb; 376(1-2):240-3. PubMed ID: 17011540
[TBL] [Abstract][Full Text] [Related]
9. Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) among Al-Ahsa Population.
Zahra MA; Kandeel M; Aldossary SA; Al-Taher A
Biomed Res Int; 2020; 2020():8765347. PubMed ID: 32626768
[TBL] [Abstract][Full Text] [Related]
10. N-acetyltransferase polymorphism among northern Sudanese.
Al-Yahyaee S; Gaffar U; Al-Ameri MM; Qureshi M; Zadjali F; Ali BH; Bayoumi R
Hum Biol; 2007 Aug; 79(4):445-52. PubMed ID: 18075007
[TBL] [Abstract][Full Text] [Related]
11. N-acetyltransferase 2 polymorphism and acetylation profiles in Buginese ethnics of Indonesia.
Yuliwulandari R; Susilowati RW; Razari I; Viyati K; Umniyati H; Prayuni K
Ann Hum Genet; 2019 Nov; 83(6):465-471. PubMed ID: 31332782
[TBL] [Abstract][Full Text] [Related]
12. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms.
García-Martín E
Curr Drug Metab; 2008 Jul; 9(6):487-97. PubMed ID: 18680468
[TBL] [Abstract][Full Text] [Related]
13. N-acetyltransferase polymorphism in patients with Behçet's disease.
Aynacioglu AS; Bozkurt A; Nacak M; Kortunay S; Tunc R; Dincel A; Kayaalp SO
Eur J Clin Pharmacol; 2001 Nov; 57(9):659-62. PubMed ID: 11791896
[TBL] [Abstract][Full Text] [Related]
14. [Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism].
Furet Y; Bechtel Y; Le Guellec C; Bechtel PR; Autret-Leca E; Paintaud G
Therapie; 2002; 57(5):427-31. PubMed ID: 12611196
[TBL] [Abstract][Full Text] [Related]
15. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphism coverage and inference of N-acetyltransferase-2 acetylator phenotypes in wordwide population groups.
Suarez-Kurtz G; Fuchshuber-Moraes M; Struchiner CJ; Parra EJ
Pharmacogenet Genomics; 2016 Aug; 26(8):363-9. PubMed ID: 27136043
[TBL] [Abstract][Full Text] [Related]
17. Clarifying haplotype ambiguity of NAT2 in multi-national cohorts.
Selinski S; Blaszkewicz M; Agundez JA; Martinez C; Garcia-Martin E; Hengstler JG; Golka K
Front Biosci (Schol Ed); 2013 Jan; 5(2):672-84. PubMed ID: 23277078
[TBL] [Abstract][Full Text] [Related]
18. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
19. N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study.
Adole PS; Kharbanda PS; Sharma S
Indian J Med Res; 2016 May; 143(5):581-90. PubMed ID: 27488001
[TBL] [Abstract][Full Text] [Related]
20. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
